First human tests begin for new Alzheimer's drug candidate in china
NCT ID NCT07346495
Summary
This is an early safety study to see how healthy Chinese adults' bodies handle a single injection of an experimental drug called remternetug. The main goal is to check for any side effects and measure how much of the drug gets into the bloodstream and how long it stays. The study will last about 25 weeks and involves 24 carefully screened, healthy volunteers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Xuhui Central Hospital
RECRUITINGXuhui District, 20031, China
Contact
-
Xuanwu Hospital Capital Medical University
RECRUITINGBeijing, 100053, China
Contact
Conditions
Explore the condition pages connected to this study.